دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
The new frontiers in prevention: from sports cardiology to spaceflight, and back to earth with cardiovascular disease and cancer
Filippo Crea
doi : 10.1093/eurheartj/ehaa1043
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 1–4
The 2020 ESC Guidelines on Sport Cardiology
Antonio Pelliccia, MD, FESC, Sanjay Sharma, MD, FESC
doi : 10.1093/eurheartj/ehaa734
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 5–6
The ‘Ten Commandments’ for the 2020 ESC Guidelines on Sports Cardiology and Exercise in Patients with Cardiovascular Disease
Sanjay Sharma, MD, FESC, Antonio Pelliccia, MD, FESC, Sabiha Gati
doi : 10.1093/eurheartj/ehaa735
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 6–7
The Australian Cardiovascular Alliance (ACvA)
Gemma Figtree, MBBS, DPHIL (OXON), FRACP, FCSANZ, FAHA, Kerry Doyle, BA PSM, Meng-Ping Hsu, PhD, Ben Freedman, OAM, A Mus A, MBBS, PhD, FRACP, FCSANZ, FAHA, FACC, FESC
doi : 10.1093/eurheartj/ehaa922
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 8–10
Don’t throw the stethoscope away!
Jian Zhu, Yan Tan, Bin Huang, Yu Zhu, Xu-Hui Gao
doi : 10.1093/eurheartj/ehaa343
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 10–12
The Italian National Association of Hospital Cardiologists and ESC look ahead to young cardiologists
Furio Colivicchi, Stefania Angela Di Fusco, Domenico Gabrielli
doi : 10.1093/eurheartj/ehaa917
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 12–13
Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems
Carlo Patrono, Massimo Volpe
doi : 10.1093/eurheartj/ehaa992
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 14–15
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease: The Task Force on sports cardiology and exercise in patients with cardiovascular disease of the European Society of Cardiology (ESC)
Antonio Pelliccia, Sanjay Sharma, Sabiha Gati, Maria B?ck, Mats B?rjesson ...
doi : 10.1093/eurheartj/ehaa605
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 17–96
The thrombotic risk of spaceflight: has a serious problem been overlooked for more than half of a century?
Ulrich Limper, Jens Tank, Tobias Ahnert, Marc Maegele, Oliver Grottke ...
doi : 10.1093/eurheartj/ehaa359
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 97–100
The first ever venous thrombotic condition associated with spaceflight, an internal jugular vein thrombus requiring anticoagulation, has recently been reported. Systematic investigation of space travel-associated thrombotic risk has not been conducted. Cellular, animal, and human studies performed in ground-based models and in actual weightlessness revealed influences of weightlessness and gravity on the blood coagulation system. However, human study populations were small and limited to highly selected participants. Evidence in individuals with medical conditions and older persons is lacking. Evidence for thrombotic risk in spaceflight is unsatisfactory. This issue deserves further study in heterogeneous, high risk populations to find prevention strategies and to enable safe governmental and touristic human spaceflight.
Long-term cardiovascular disease mortality among 160 834 5-year survivors of adolescent and young adult cancer: an American population-based cohort study
Lai Wang, Fengjiao Wang, Lianyu Chen, Yawen Geng, Shulin Yu ...
doi : 10.1093/eurheartj/ehaa779
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 101–109
Our aim was to assess the risk of cardiovascular disease (CVD) mortality in US 5-year survivors of adolescent and young adult (AYA) cancer compared with those of the general population and contemporaneous 5-year survivors of childhood cancer.
Cancer and cardiovascular mortality risk: is the die cast?
Patrizio Lancellotti, Mai-Linh Nguyen Trung, Cécile Oury, Marie Moonen
doi : 10.1093/eurheartj/ehaa871
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 110–112
Targeting cardiovascular inflammation: next steps in clinical translation
Patrick R Lawler, Deepak L Bhatt, Lucas C Godoy, Thomas F Lüscher, Robert O Bonow ...
doi : 10.1093/eurheartj/ehaa099
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 113–131
Systemic vascular inflammation plays multiple maladaptive roles which contribute to the progression and destabilization of atherosclerotic cardiovascular disease (ASCVD). These roles include: (i) driving atheroprogression in the clinically stable phase of disease; (ii) inciting atheroma destabilization and precipitating acute coronary syndromes (ACS); and (iii) responding to cardiomyocyte necrosis in myocardial infarction (MI).
Time for clinicians to revisit their perspectives on C-statistic
Arya Aminorroaya, Masih Tajdini, Farzad Masoudkabir
doi : 10.1093/eurheartj/ehaa859
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 132–133
Model assessment: new measures should be known and traditional measures should be accurately interpreted
Shen Lin, Sipeng Chen, Zheng Zhe
doi : 10.1093/eurheartj/ehaa882
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Pages 134–135
Ventricular tachycardia vs. supraventricular tachycardia with aberrancy
Garry W. Hamilton, Han S. Lim
doi : 10.1093/eurheartj/ehaa636
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Page 133
Let’s stroll: the idiosyncratic journey of a cropped pacer-wire
Manuel Wilbring, Martin Schmidt, Klaus-Peter Günther, Klaus Matschke
doi : 10.1093/eurheartj/ehaa594
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Page 136
A ‘Mille-Feuille’-like giant dissecting aneurysm of the pulmonary artery in Eisenmenger syndrome
Kazuhiro Kamada, Kazuya Hosokawa, Kota Inoue, Kohtaro Abe
doi : 10.1093/eurheartj/ehaa513
European Heart Journal, Volume 42, Issue 1, 1 January 2021, Page 137
Machine learning-guided phenotyping of dilated cardiomyopathy and treatment of heart failure by antisense oligonucleotides: the future has begun
Filippo Crea
doi : 10.1093/eurheartj/ehaa1063
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 139–142
The ESC Working Group on e-Cardiology
Polychronis Dilaveris, Joost Lumens
doi : 10.1093/eurheartj/ehaa401
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 143–144
Virtual medical education during the COVID-19 pandemic: how to make it work
Amr Idris, MD, Basel Edris, MD
doi : 10.1093/eurheartj/ehaa638
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 145–146
The Danish Society of Cardiology
Steen Dalby Kristensen, MD, DMSc, FESC, Jacob Thorsted Sorensen, MD, PhD
doi : 10.1093/eurheartj/ehaa920
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 147–148
The Syncope Unit of Tehran Heart Center
Saeed Sadeghian, MD, Arya Aminorroaya, MD, Masih Tajdini, MD
doi : 10.1093/eurheartj/ehaa532
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 148–150
COVID 19: in the eye of the cytokine storm
Giovanna Liuzzo, MD, PhD, FESC, Carlo Patrono, MD, FESC
doi : 10.1093/eurheartj/ehaa1005
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 150–151
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
Rajiv Agarwal, Peter Kolkhof, George Bakris, Johann Bauersachs, Hermann Haller ...
doi : 10.1093/eurheartj/ehaa736
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 152–161
This review covers the last 80?years of remarkable progress in the development of mineralocorticoid receptor (MR) antagonists (MRAs) from synthesis of the first mineralocorticoid to trials of nonsteroidal MRAs. The MR is a nuclear receptor expressed in many tissues/cell types including the kidney, heart, immune cells, and fibroblasts. The MR directly affects target gene expression—primarily fluid, electrolyte and haemodynamic homeostasis, and also, but less appreciated, tissue remodelling.
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences
Job A J Verdonschot, Marco Merlo, Fernando Dominguez, Ping Wang, Michiel T H M Henkens ...
doi : 10.1093/eurheartj/ehaa841
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 162–174
The dilated cardiomyopathy (DCM) phenotype is the result of combined genetic and acquired triggers. Until now, clinical decision-making in DCM has mainly been based on ejection fraction (EF) and NYHA classification, not considering the DCM heterogenicity. The present study aimed to identify patient subgroups by phenotypic clustering integrating aetiologies, comorbidities, and cardiac function along cardiac transcript levels, to unveil pathophysiological differences between DCM subgroups.
Personalized medicine for dilated cardiomyopathy
Perry M Elliott
doi : 10.1093/eurheartj/ehaa869
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 175–177
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study
J?rg T?ubel, Wilfried Hauke, Steffen Rump, Janika Viereck, Sandor Batkai ...
doi : 10.1093/eurheartj/ehaa898
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 178–188
Cardiac microRNA-132-3p (miR-132) levels are increased in patients with heart failure (HF) and mechanistically drive cardiac remodelling processes. CDR132L, a specific antisense oligonucleotide, is a first-in-class miR-132 inhibitor that attenuates and even reverses HF in preclinical models. The aim of the current clinical Phase 1b study was to assess safety, pharmacokinetics, target engagement, and exploratory pharmacodynamic effects of CDR132L in patients on standard-of-care therapy for chronic ischaemic HF in a randomized, placebo-controlled, double-blind, dose-escalation study (NCT04045405).
Antagonism of miRNA in heart failure: first evidence in human
Andrew H Baker, Mauro Giacca
doi : 10.1093/eurheartj/ehaa967
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 189–191
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure
Sandor Batkai, Celina Genschel, Janika Viereck, Steffen Rump, Christian B?r ...
doi : 10.1093/eurheartj/ehaa791
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 192–201
Cardiac miR-132 activation leads to adverse remodelling and pathological hypertrophy. CDR132L is a synthetic lead-optimized oligonucleotide inhibitor with proven preclinical efficacy and safety in heart failure (HF) early after myocardial infarction (MI), and recently completed clinical evaluation in a Phase 1b study (NCT04045405). The aim of the current study was to assess safety and efficacy of CDR132L in a clinically relevant large animal (pig) model of chronic heart failure following MI.
CDR132L: another brick in the wall towards the use of miRNAs to treat cardiovascular disease
Yvan Devaux, Lina Badimon
doi : 10.1093/eurheartj/ehaa870
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 202–204
Posture dependent dynamic external outflow graft compression in HeartMate 3TM left ventricular assist device
Monika Fürholz, Fabian Gisler, Lukas Hunziker, Adrian T Huber, Christoph Gr?ni
doi : 10.1093/eurheartj/ehaa362
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Page 205
Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin
Hongde Hu, Fenglian Ma, Xin Wei, Yuan Fang
doi : 10.1093/eurheartj/ehaa190
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Page 206
End-stage heart failure secondary to low-dose hydroxychloroquine treatment
Stefano Figliozzi, Stefania Rizzo, Monica De Gaspari, Giuseppe Tarantini
doi : 10.1093/eurheartj/ehaa595
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Page 207
Pulmonary ventilation–perfusion mismatch demonstrated by dynamic chest radiography in giant cell arteritis
Yuzo Yamasaki, Kazuya Hosokawa, Hiroyuki Tsutsui, Kousei Ishigami
doi : 10.1093/eurheartj/ehaa443
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Pages 208–209
Corrigendum to: How to slice the pie: heart failure subgroups and their clinical meaning
doi : 10.1093/eurheartj/ehaa613
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Page 177
Corrigendum to: Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin
doi : 10.1093/eurheartj/ehaa248
European Heart Journal, Volume 42, Issue 2, 7 January 2021, Page 191
Risk stratification and treatment of acute and chronic coronary syndromes: focus on angina without obstructive coronary arteries, refractory angina, lipids, and clonal haematopoiesis
Filippo Crea
doi : 10.1093/eurheartj/ehaa1094
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 211–214
The Impact of COVID-19 on the Continuity of Cardiovascular Care
Raghav T Bhatia, Sabiha Gati, Michael Papadakis, Sanjay Sharma
doi : 10.1093/eurheartj/ehaa742
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 215–217
Professor Giuseppe Mancia
Mark Nicholls
doi : 10.1093/eurheartj/ehaa611
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 218–219
ESC Congress 2020 - Nursing and Allied Professions Investigator Award
Mark Nicholls
doi : 10.1093/eurheartj/ehaa786
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Page 220
Peter Sleight, Emeritus Professor of Cardiovascular Medicine, Oxford University, Chairman of the ISIS Trials Steering Committee
Nick Boon, MD, FRCP, Salim Yusuf, DPhil, FRCPC, FRSC, O.C
doi : 10.1093/eurheartj/ehaa1009
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 221–223
The EHJ Weekly Journal Scan: Why? Who? How?
Carlo Patrono
doi : 10.1093/eurheartj/ehaa978
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 224–226
Preventing a diabetes pandemic through lifestyle intervention
Leonarda Galiuto, Carlo Patrono
doi : 10.1093/eurheartj/ehaa1018
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 226–227
Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study
Jakob Schroder, Marie M Michelsen, Naja D Mygind, Hannah E Suhrs, Kira B Bove ...
doi : 10.1093/eurheartj/ehaa944
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 228–239
The curious incident of CFVR in clinical practice
Rosa Sicari
doi : 10.1093/eurheartj/ehaa1006
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 240–242
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study
Jessica Schubert, Bertil Lindahl, H?kan Melhus, Henrik Renlund, Margrét Leosdottir ...
doi : 10.1093/eurheartj/ehaa1011
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 243–252
Clinical trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular (CV) events. This has, however, not yet been shown in a real-world setting. We aimed to investigate the association between LDL-C changes and statin intensity with prognosis after a myocardial infarction (MI).
Changing the paradigm for post-MI cholesterol lowering from intensive statin monotherapy towards intensive lipid-lowering regimens and individualized care
Kausik K Ray
doi : 10.1093/eurheartj/ehaa1008
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 253–256
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations
Birgit Assmus, Sebastian Cremer, Klara Kirschbaum, David Culmann, Katharina Kiefer ...
doi : 10.1093/eurheartj/ehaa845
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 257–265
Somatic mutations of the epigenetic regulators DNMT3A and TET2 causing clonal expansion of haematopoietic cells (clonal haematopoiesis; CH) were shown to be associated with poor prognosis in chronic ischaemic heart failure (CHF). The aim of our analysis was to define a threshold of variant allele frequency (VAF) for the prognostic significance of CH in CHF.
Clonal haematopoiesis and cardiovascular disease: how low can you go?
Megan A Evans, Soichi Sano, Kenneth Walsh
doi : 10.1093/eurheartj/ehaa848
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 266–268
Management of refractory angina: an update
Allan Davies, Kim Fox, Alfredo R Galassi, Shmuel Banai, Seppo Yl?-Herttuala ...
doi : 10.1093/eurheartj/ehaa820
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 269–283
Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3?months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting.
Intestinal cholesterol and phytosterol absorption and the risk of coronary artery disease
Jogchum Plat, Timo E Strandberg, Helena Gylling
doi : 10.1093/eurheartj/ehaa881
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 281–282
Increased absorption of phytosterols is the simplest and most plausible explanation for coronary artery disease risk not accounted for by non-HDL cholesterol in high cholesterol absorbers
Anna Helgadottir, Gudmar Thorleifsson, Kari Stefansson
doi : 10.1093/eurheartj/ehaa902
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 283–284
Pericardial agenesis: a rare cause of chest pain
C?tia Costa Oliveira, Catarina Vieira, Nuno Bettencourt, Vitor Hugo Pereira
doi : 10.1093/eurheartj/ehaa666
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Page 282
Significant pinching of dominant left circumflex artery during provisional left main bifurcation angioplasty: what next?
Ankush Gupta, Sanya Chhikara
doi : 10.1093/eurheartj/ehaa989
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Page 285
Diagnosis of acute myocardial infarction in the time of the COVID-19 pandemic
Marco Mele, Grazia Casavecchia, Riccardo Ieva, Natale Daniele Brunetti
doi : 10.1093/eurheartj/ehaa914
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Page 286
Culprit mistaken: development of a traumatic coronary aneurysm after mismatched culprit lesion-PCI for plaque rupture
Youssef S Abdelwahed, Thomas H Wurster, Ulf Landmesser, David M Leistner
doi : 10.1093/eurheartj/ehaa748
European Heart Journal, Volume 42, Issue 3, 14 January 2021, Page 287
Management of ischaemic stroke, prognostic impact of procedural myocardial injury, and antiplatelet treatment: the many facets of interventional cardiology
Filippo Crea
doi : 10.1093/eurheartj/ehab001
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 289–291
The Experience of a Plasma Donor
Sameer Gupta, Dr, FACC FSCAI
doi : 10.1093/eurheartj/ehaa863
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 292–293
Becoming a Cardiologist: Is it sporadic, inherited or is it a combination of genetics and environment?
Christoph Gr?ni, MD, PhD
doi : 10.1093/eurheartj/ehaa188
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 293–294
The Cardiology Society of Serbia
Sinisa Stojkovic, MD PhD, Milorad Tesic, MD
doi : 10.1093/eurheartj/ehaa236
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 294–296
Truly galactic?
Volpe Massimo, Patrono Carlo
doi : 10.1093/eurheartj/ehaa1017
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 296–297
Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention
Sandor Nardai, Peter Lanzer, Mark Abelson, Andreas Baumbach, Wolfram Doehner ...
doi : 10.1093/eurheartj/ehaa833
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 298–307
This ESC Council on Stroke/EAPCI/EBNI position paper summarizes recommendations for training of cardiologists in endovascular treatment of acute ischaemic stroke. Interventional cardiologists adequately trained to perform endovascular stroke interventions could complement stroke teams to provide the 24/7 on call duty and thus to increase timely access of stroke patients to endovascular treatment. The training requirements for interventional cardiologists to perform endovascular therapy are described in details and should be based on two main principles: (i) patient safety cannot be compromised, (ii) proper training of interventional cardiologists should be under supervision of and guaranteed by a qualified neurointerventionist and within the setting of a stroke team. Interdisciplinary cooperation based on common standards and professional consensus is the key to the quality improvement in stroke treatment.
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials
Daniele Giacoppo, Yuji Matsuda, Luca Nai Fovino, Gianpiero D’Amico, Giuseppe Gargiulo ...
doi : 10.1093/eurheartj/ehaa739
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 308–319
After percutaneous coronary intervention (PCI) with second-generation drug-eluting stent (DES), whether short dual antiplatelet therapy (DAPT) followed by single antiplatelet therapy (SAPT) with a P2Y12 receptor inhibitor confers benefits compared with prolonged DAPT is unclear.
Aspirin or P2Y12 inhibition: establishing the cornerstone of antiplatelet therapy after stenting
Michelle L O’Donoghue, Marc S Sabatine
doi : 10.1093/eurheartj/ehaa741
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 320–322
Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patient-level data
Johanne Silvain, Michel Zeitouni, Valeria Paradies, Huili L Zheng, Gjin Ndrepepa ...
doi : 10.1093/eurheartj/ehaa885
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 323–334
The prognostic importance of cardiac procedural myocardial injury and myocardial infarction (MI) in chronic coronary syndrome (CCS) patients undergoing elective percutaneous coronary intervention (PCI) is still debated.
Cardiac troponin elevation after elective PCI: adding infarct to major injury
Brian A Bergmark, David A Morrow
doi : 10.1093/eurheartj/ehaa983
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 335–338
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey
Davide Cao, Rishi Chandiramani, Mauro Chiarito, Bimmer E Claessen, Roxana Mehran
doi : 10.1093/eurheartj/ehaa824
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 339–351
Since its introduction in 1977, percutaneous coronary intervention has become one of the most commonly performed therapeutic procedures worldwide. Such widespread diffusion, however, would have not been possible without a concomitant evolution of the pharmacotherapies associated with this intervention. Antithrombotic agents are fundamental throughout the management of patients undergoing coronary stent implantation, starting from the procedure itself to the long-term prevention of cardiovascular events.
High-risk NSTE-ACS: high time for robust data
Thomas A Kite, Anthony H Gershlick
doi : 10.1093/eurheartj/ehaa927
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 352
Optimal timing of invasive angiography in non-ST-segment elevation acute coronary syndromes—do we need more data?
Alexander Jobs, Jean-Philippe Collet, Holger Thiele
doi : 10.1093/eurheartj/ehaa930
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 353–354
Risk stratification refinement and implantable cardioverter defibrillator protection for the coronary artery disease patients with a preserved left ventricular systolic function with a two-step programmed ventricular stimulation-inclusive approach
Petros Arsenos, Christos-Konstantinos Antoniou, Konstantinos A Gatzoulis
doi : 10.1093/eurheartj/ehaa772
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Pages 355–356
Gone with wind: a novel biodegradable occluder for percutaneous closure of patent foramen ovale
Gangcheng Zhang, Qunshan Shen, Dingyang Li, Xuan Zheng
doi : 10.1093/eurheartj/ehaa807
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 354
First-in-man proof of feasibility: PCI, TAVR, and TEVAR of aortic arch with a hybrid approach through a trans-caval (cavo-aortic) access in the same procedure
A B Gopalamurugan, R Anantharaman, Mohamed Abubacker, G Manju Varshaa, Prashant Vaijyanath
doi : 10.1093/eurheartj/ehaa529
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 357
Transcatheter aortic valve lithotripsy in severely calcified bicuspid aortic stenosis prior to transcatheter aortic valve implantation
Alok Sharma, Stefan Bertog, Mackenzie Mbai
doi : 10.1093/eurheartj/ehaa829
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 358
Three-dimensional echo guidance of percutaneous mitral paravalvular leak closure
Alessandra Quercioli, Anna Clizia Capettini, Riccardo Gherli, Gioel Gabrio Secco
doi : 10.1093/eurheartj/ehaa593
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 359
Corrigendum to: Interdisciplinary management of acute ischaemic stroke: Current evidence training requirements for endovascular stroke treatment: Position Paper from the ESC Council on Stroke and the European Association for Percutaneous Cardiovascular Interventions with the support of the European Board of Neurointervention
doi : 10.1093/eurheartj/ehaa1004
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 307
Corrigendum to: Does hypoperfusion outperform blood pressure as a better predictor in the risk stratification of acute heart failure?
doi : 10.1093/eurheartj/ehaa753
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 319
Corrigendum to: Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era
doi : 10.1093/eurheartj/ehaa690
European Heart Journal, Volume 42, Issue 4, 21 January 2021, Page 322
